Zacks Research Forecasts Humana’s FY2025 Earnings (NYSE:HUM)

Humana Inc. (NYSE:HUM) – Stock analysts at Zacks Research boosted their FY2025 earnings per share estimates for shares of Humana in a report issued on Wednesday, August 13th. Zacks Research analyst D. Chatterjee now anticipates that the insurance provider will post earnings of $16.99 per share for the year, up from their previous estimate of $16.25. The consensus estimate for Humana’s current full-year earnings is $16.47 per share. Zacks Research also issued estimates for Humana’s Q2 2027 earnings at $6.95 EPS.

Several other equities analysts have also recently issued reports on HUM. Barclays set a $275.00 target price on Humana and gave the stock an “equal weight” rating in a research report on Thursday, July 31st. Cantor Fitzgerald reiterated a “neutral” rating and set a $290.00 target price on shares of Humana in a research report on Thursday, May 1st. Robert W. Baird dropped their target price on Humana from $300.00 to $297.00 and set a “neutral” rating on the stock in a research report on Friday, July 25th. Bank of America dropped their target price on Humana from $320.00 to $260.00 and set a “neutral” rating on the stock in a research report on Tuesday, June 17th. Finally, Truist Financial lowered their price target on Humana from $280.00 to $260.00 and set a “hold” rating on the stock in a report on Wednesday, July 16th. Seventeen research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $281.43.

Humana Stock Performance

Shares of HUM stock opened at $286.73 on Friday. The stock has a market capitalization of $34.49 billion, a PE ratio of 22.01, a price-to-earnings-growth ratio of 1.68 and a beta of 0.44. Humana has a 52-week low of $206.87 and a 52-week high of $382.72. The stock’s 50-day moving average price is $242.70 and its 200 day moving average price is $253.54. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.32 by ($0.05). The company had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The business’s revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the firm earned $6.96 EPS.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in HUM. Revolve Wealth Partners LLC purchased a new position in shares of Humana during the 4th quarter worth $202,000. Raymond James Financial Inc. purchased a new position in shares of Humana during the 4th quarter worth $26,720,000. Mariner LLC lifted its stake in shares of Humana by 4.0% during the 4th quarter. Mariner LLC now owns 13,461 shares of the insurance provider’s stock worth $3,415,000 after purchasing an additional 517 shares during the period. Canada Post Corp Registered Pension Plan purchased a new position in shares of Humana during the 4th quarter worth $271,000. Finally, Insigneo Advisory Services LLC lifted its stake in shares of Humana by 17.3% during the 4th quarter. Insigneo Advisory Services LLC now owns 1,360 shares of the insurance provider’s stock worth $345,000 after purchasing an additional 201 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.